{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:10:30Z","timestamp":1789783830816,"version":"4.0.1"},"reference-count":20,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,7,24]],"date-time":"2008-07-24T00:00:00Z","timestamp":1216857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold><jats:styled-content>Purpose:<\/jats:styled-content>\u2002<\/jats:bold> To evaluate efficacy and tolerability of levetiracetam (LEV; Keppra<jats:sup>\u00ae<\/jats:sup>) as add\u2010on therapy in Chinese patients with refractory partial\u2010onset seizures.<\/jats:p><jats:p><jats:bold><jats:styled-content>Methods:<\/jats:styled-content>\u2002<\/jats:bold> In this multicenter, double\u2010blind, randomized, placebo\u2010controlled trial, 206 patients aged 16\u201370 years with uncontrolled partial\u2010onset seizures were randomized to receive LEV (n\u00a0=103) or placebo (n\u00a0=103); 202 patients (LEV, n\u00a0=102; placebo, n\u00a0= 100) comprised the intent\u2010to\u2010treat population. An 8\u2010week historical baseline period confirmed eligibility according to seizure count. The 16\u2010week treatment period consisted of a 4\u2010week up\u2010titration period (LEV, 1,000\u20133,000 mg\/day in two equal divided doses) followed by a 12\u2010week maintenance period. Efficacy assessments were based on weekly frequency of partial\u2010onset seizures during the 16\u2010week treatment period.<\/jats:p><jats:p><jats:bold><jats:styled-content>Results:<\/jats:styled-content>\u2002<\/jats:bold> LEV significantly decreased weekly partial\u2010onset seizure frequency over placebo by 26.8% (p\u00a0 &lt; 0.001). Median percentage reductions in weekly partial\u2010onset seizure frequency from historical baseline were 55.9% for LEV and 13.7% for placebo (p\u00a0 &lt; 0.001). The \u226550% responder rates were 55.9% for LEV, compared with 26.0% for placebo (p\u00a0 &lt; 0.001). Freedom from partial\u2010onset seizures during treatment period was achieved by 11 LEV patients (10.8%) and 2 placebo patients (2.0%) (p\u00a0= 0.012). Adverse events were reported by 65 LEV\u2010treated patients (63.1%) and 62 placebo\u2010treated patients (60.2%); most were of mild\u2010to\u2010moderate intensity. The most common adverse events were somnolence (LEV, 17.5%; placebo, 17.5%), decreased platelet count (LEV, 9.7%; placebo, 9.7%), and dizziness (LEV, 7.8%; placebo, 13.6%).<\/jats:p><jats:p><jats:bold><jats:styled-content>Discussion:<\/jats:styled-content>\u2002<\/jats:bold> Add\u2010on LEV was effective and well\u2010tolerated in Chinese patients with refractory partial\u2010onset seizures.<\/jats:p>","DOI":"10.1111\/j.1528-1167.2008.01729.x","type":"journal-article","created":{"date-parts":[[2008,7,24]],"date-time":"2008-07-24T19:37:52Z","timestamp":1216928272000},"page":"398-405","source":"Crossref","is-referenced-by-count":46,"title":["Multicenter double\u2010blind, randomized, placebo\u2010controlled trial of levetiracetam as add\u2010on therapy in Chinese patients with refractory partial\u2010onset seizures"],"prefix":"10.1111","volume":"50","author":[{"given":"Xun\u2010Yi","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li\u2010Wen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue\u2010Feng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong\u2010Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan\u2010Zhen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,3,4]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb04605.x"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000268699.34614.d3"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000252941.50833.4a"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.2.236"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2007.00004.x"},{"key":"e_1_2_6_7_1","unstructured":"European Commission. (1991)Guidelines for good clinical practice. Directive 91\/507\/EEC 19 July."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000217916.00225.3a"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2007.02.011"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2007.11.021"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.2000.0689"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01381.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000297512.18364.40"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200443110-00002"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(02)00250-4"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200746060-00004"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb00323.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-003-0655-6"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02782.x"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1528-1167.2008.01729.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1528-1167.2008.01729.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T15:58:18Z","timestamp":1697126298000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1528-1167.2008.01729.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1528-1167.2008.01729.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1528-1167.2008.01729.x","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}